Inhibitor Therapeutics (INTI) Assets Average (2013 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Assets Average came in at $2.0 million in Q1 2026, down 61.33% YoY from $5.1 million in Q1 2025, and down 30.14% on a QoQ basis from $2.8 million in Q4 2025.
Inhibitor Therapeutics (INTI) Assets Average (2013 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 14 years of Assets Average data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Assets Average fell 61.33% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 61.33% YoY) and the FY2025 annual result came in at $4.1 million, down 43.96% from the prior year.
- Assets Average retreated to $2.0 million in Q1 2026, from $2.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $11.4 million in Q1 2023 to a low of $49830.0 in Q2 2022.
- A 5-year average of $5.5 million and a median of $6.0 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average slumped 63.71% — and 2023, when it jumped 20965.14%.
- Tracing INTI's Assets Average over 5 years: stood at $6.0 million in 2022, then soared by 54.15% to $9.3 million in 2023, then sank by 34.55% to $6.1 million in 2024, then sank by 53.51% to $2.8 million in 2025, then plunged by 30.14% to $2.0 million in 2026.
- The last three Assets Average figures came in at $2.0 million (Q1 2026), $2.8 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.97 Mn |
| Dec 31, 2025 | 2.82 Mn |
| Sep 30, 2025 | 3.52 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Sep 30, 2024 | 6.81 Mn |
| Jun 30, 2024 | 7.48 Mn |
| Mar 31, 2024 | 8.37 Mn |
| Dec 31, 2023 | 9.28 Mn |
| Sep 30, 2023 | 9.88 Mn |
| Jun 30, 2023 | 10.50 Mn |
| Mar 31, 2023 | 11.41 Mn |
| Dec 31, 2022 | 6.02 Mn |
| Sep 30, 2022 | 50,817.00 |
| Jun 30, 2022 | 49,830.00 |
| Mar 31, 2022 | 59,963.50 |
| Dec 31, 2021 | 75,651.00 |
| Sep 30, 2021 | 114,519.00 |
| Jun 30, 2021 | 137,293.00 |